Esperion completes patient enrollment in Phase 3 program for bempedoic acid
Esperion Therapeutics announced the completion of patient enrollment in the global pivotal phase 3 program for bempedoic acid. Top-line results from Studies 1, 3 and 4 are expected in the second quarter of 2018, with top-line results from Study 2 expected in the third quarter of 2018. The pivotal Phase 3 program for the bempedoic acid / ezetimibe combination pill remains on track to initiate this quarter, with top-line results expected by the fourth quarter of 2018. The four Phase 3 studies comprising the global pivotal Phase 3 program for bempedoic acid along with the single Phase 3 bridging study for the combination pill are expected to support two New Drug Application submissions for LDL-C lowering indications for the bempedoic acid / ezetimibe combination pill and bempedoic acid by the first quarter of 2019.